GO:1902247 geranylgeranyl diphosphate catabolic process: Isoprenoid Metabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902247 describes the biological process that breaks down geranylgeranyl diphosphate (GGPP), a central 20-carbon isoprenoid intermediate.
• GGPP catabolism controls the availability of the substrate used for protein geranylgeranylation, a post-translational modification of small GTPases such as RHO, RAC and RAB.
• The mevalonate pathway supplies GGPP, and its catabolic removal is a key node connecting metabolism to cell signaling, immune cell fate and oocyte quality.
• GGDPS (geranylgeranyl diphosphate synthase) is the enzyme that produces GGPP; its inhibition or loss shifts the balance toward catabolism and is studied in cancer and metabolic disease.
• GGPP catabolic flux can be modeled experimentally with knockout, point-mutation and overexpression cell models, and measured by metabolomics, prenylation assays and imaging.
• Understanding GO:1902247 helps researchers interpret how statins, bisphosphonates and metabolic interventions alter isoprenoid signaling in disease.
Description
Geranylgeranyl diphosphate (GGPP) is a 20-carbon isoprenoid produced by the mevalonate pathway and used as a substrate for protein geranylgeranylation, a lipid modification that anchors small GTPases to membranes. The Gene Ontology term GO:1902247, geranylgeranyl diphosphate catabolic process, describes the chemical reactions and pathways that result in the breakdown of GGPP. Because GGPP sits at the intersection of sterol biosynthesis, prenylation and cell signaling, its catabolic removal is not merely a disposal step but a regulatory node that influences cell growth, differentiation and stress responses. Researchers study GO:1902247 to understand how cells balance the production and consumption of isoprenoid intermediates. When GGPP catabolism is altered, the prenylation of RHO, RAC, RAB and other small GTPases changes, affecting cytoskeletal dynamics, vesicle trafficking and immune cell function. This term is therefore relevant to cancer biology, autoimmunity, aging and metabolic disease, where mevalonate pathway flux and GGPP levels are frequently dysregulated. This article summarizes the authoritative QuickGO definition, the biochemical steps and protein components involved, the genes and experimental models used to study GGPP catabolism, and the disease contexts in which this process matters. All statements are based on the verified PubMed literature listed at the end.
geranylgeranyl diphosphate catabolic process At A Glance
| GO ID | GO:1902247 |
|---|---|
| GO term | geranylgeranyl diphosphate catabolic process |
| Ontology | biological_process |
| Synonym | geranylgeranyl diphosphate breakdown; geranylgeranyl diphosphate catabolism; geranylgeranyl diphosphate degradation |
| Major function | Breakdown of the 20-carbon isoprenoid GGPP, controlling substrate availability for protein geranylgeranylation and downstream isoprenoid metabolism |
| Substrate | Geranylgeranyl diphosphate (GGPP) |
| Related biosynthetic enzyme | GGDPS (geranylgeranyl diphosphate synthase) produces GGPP and is a therapeutic target in cancer |
| Pathway context | Mevalonate pathway and isoprenoid metabolism |
| Disease relevance | Cancer, autoimmunity, aging and metabolic disorders |
What Is GO:1902247?
GO:1902247 (geranylgeranyl diphosphate catabolic process) is defined by QuickGO as the chemical reactions and pathways resulting in the breakdown of geranylgeranyl diphosphate. In practical terms, it covers the enzymatic and spontaneous conversions that remove GGPP from the cellular pool, including dephosphorylation, isomerization, oxidative cleavage and conversion into downstream isoprenoid products. Synonyms include geranylgeranyl diphosphate breakdown, geranylgeranyl diphosphate catabolism and geranylgeranyl diphosphate degradation. The process is a biological_process aspect of the Gene Ontology and is distinct from GGPP biosynthetic processes, although both contribute to the steady-state level of this metabolite.
Why Is geranylgeranyl diphosphate catabolic process Important in Cell Biology?
GGPP catabolism is important because it sets the cellular concentration of the major substrate for protein geranylgeranylation, a modification required for the membrane localization and function of small GTPases such as RHO, RAC and RAB. Changes in GGPP breakdown therefore propagate to cytoskeletal organization, vesicle trafficking, immune signaling and cell proliferation. Pharmacological agents that block the mevalonate pathway, including statins and bisphosphonates, indirectly alter GGPP availability and have been linked to effects on cholesterol transport and monocyte function. In cancer, GGDPS and GGPP-dependent prenylation are actively investigated as therapeutic vulnerabilities. In aging, mevalonate metabolites and prenylation of small GTPases influence oocyte quality, highlighting the physiological importance of GGPP homeostasis.
• Controls the substrate pool for geranylgeranylation of RHO, RAC and RAB small GTPases.
• Links mevalonate pathway flux to immune cell fate, including T follicular helper cell generation.
• Modulates mononuclear phagocyte morphology and chemotaxis through GGPP-dependent prenylation.
• Represents a metabolic node targeted indirectly by statins and bisphosphonates.
• GGDPS, the enzyme upstream of GGPP, is a candidate cancer therapeutic target.
• GGPP catabolism contributes to the regulation of prenylquinone and isoprenoid biosynthesis.
• Altered GGPP metabolism is associated with aging-related decline in oocyte quality.
• Provides a mechanistic explanation for how metabolic interventions affect cell signaling.
• Supports the interpretation of metabolomic and prenylation data in disease models.
• Offers a point of intervention for modulating isoprenoid-dependent cellular processes.
What Happens During geranylgeranyl diphosphate catabolic process?
Dephosphorylation and hydrolysis of GGPP
In simple terms: GGPP is a molecule with two phosphate groups; removing them is one way the cell breaks it down.
The catabolic process begins with the removal of the diphosphate moiety from GGPP, yielding geranylgeraniol and related alcohols. This step reduces the pool of GGPP available for prenyltransferases and is part of the broader isoprenoid catabolic network. The reaction can be enzymatic or spontaneous, and its balance with GGPP synthesis determines the steady-state concentration of the metabolite.
Conversion to downstream isoprenoid products
In simple terms: Instead of being destroyed, GGPP can be converted into other useful molecules, which also removes it from the prenylation pool.
GGPP serves as a precursor for the biosynthesis of prenylquinones such as ubiquinone and plastoquinone, as well as for carotenoids and other isoprenoids in various organisms. When GGPP is channeled into these pathways, it is effectively consumed and no longer available for protein geranylgeranylation. This branching is a key determinant of whether GGPP supports prenylation or is directed toward catabolic and biosynthetic fates.
Oxidative and non-enzymatic degradation
In simple terms: GGPP can also be broken down by chemical reactions such as oxidation, especially under stress.
Isoprenoid diphosphates are chemically reactive and can undergo oxidative cleavage and other non-enzymatic modifications. These reactions contribute to the catabolic removal of GGPP and generate products that may feed into other metabolic routes. The extent of non-enzymatic degradation depends on cellular redox status and the presence of protective enzymes.
Coupling to protein geranylgeranylation
In simple terms: When GGPP is used to modify proteins, it is consumed, which is a major route of its removal from the free pool.
Protein geranylgeranyltransferases use GGPP as a substrate to attach a geranylgeranyl group to cysteine residues of target proteins such as RHO, RAC and RAB GTPases. This covalent modification is effectively a catabolic fate for GGPP because the metabolite is no longer free. The rate of geranylgeranylation therefore directly influences GGPP catabolic flux, and changes in prenyltransferase activity can shift the balance between free and protein-bound GGPP.
Regulation by mevalonate pathway flux
In simple terms: The amount of GGPP available for breakdown depends on how much the mevalonate pathway produces.
The mevalonate pathway supplies GGPP through the sequential action of HMG-CoA reductase, farnesyl diphosphate synthase and GGDPS. When pathway flux increases, more GGPP is available for both prenylation and catabolism; when flux decreases, catabolic removal is limited by substrate availability. This coupling means that GO:1902247 is regulated indirectly by upstream biosynthetic enzymes and by the demand for prenylated proteins.
Key Genes Involved in GO:1902247 geranylgeranyl diphosphate catabolic process
The following genes and proteins are functionally linked to geranylgeranyl diphosphate catabolic process, either by producing or consuming GGPP, by using it for prenylation, or by regulating mevalonate pathway flux.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GGDPS | Produces GGPP from farnesyl diphosphate; upstream of catabolism | Cancer therapy target; determines substrate availability for GO:1902247 |
| HMGCR | Rate-limiting enzyme of the mevalonate pathway | Target of statins; modulates GGPP levels and catabolic flux |
| FDPS | Generates farnesyl diphosphate, the precursor of GGPP | Links sterol and non-sterol isoprenoid branches |
| RHO | Small GTPase modified by geranylgeranylation | Readout of GGPP-dependent prenylation |
| RAC1 | Small GTPase modified by geranylgeranylation | Controls cytoskeleton and immune signaling |
| RAB | Family of small GTPases requiring geranylgeranylation | Regulates vesicle trafficking; sensitive to GGPP catabolism |
| PGGT1B | Catalytic subunit of geranylgeranyltransferase I | Consumes GGPP for protein prenylation |
| RABGGTA | Subunit of geranylgeranyltransferase II | Mediates RAB geranylgeranylation and GGPP consumption |
| FNTA | Farnesyltransferase/geranylgeranyltransferase alpha subunit | Shared subunit for prenyltransferases |
| FNTB | Farnesyltransferase beta subunit | Distinguishes farnesyl vs geranylgeranyl transfer |
| ABCA1 | Cholesterol efflux transporter | Modulated by bisphosphonates and mevalonate metabolites |
| SQLE | Squalene epoxidase in sterol synthesis | Competes with GGPP for mevalonate pathway flux |
| MVK | Mevalonate kinase | Mutations cause mevalonate kinase deficiency and alter isoprenoid flux |
| PMVK | Phosphomevalonate kinase | Contributes to mevalonate pathway output |
| MVD | Mevalonate diphosphate decarboxylase | Supplies isopentenyl diphosphate for GGPP synthesis |
| IDI1 | Isopentenyl diphosphate isomerase | Balances isoprenoid precursors for GGPP production |
| GGPS1 | Alternative symbol for GGDPS | Studied in cancer and metabolic models |
How Is geranylgeranyl diphosphate catabolic process Regulated?
The geranylgeranyl diphosphate catabolic process is regulated primarily by the availability of GGPP, which in turn depends on mevalonate pathway flux and the activity of GGDPS. Upstream signals such as T cell receptor engagement modulate the mevalonate pathway and influence GGPP-dependent processes in immune cells. Pharmacological inhibition of HMG-CoA reductase by statins reduces GGPP synthesis and indirectly limits catabolic flux. Bisphosphonates can also affect isoprenoid metabolism and cholesterol transport in monocytoid cells. In addition, the demand for protein geranylgeranylation acts as a sink that consumes GGPP and drives its removal from the free pool. Feedback regulation of sterol biosynthesis can further adjust pathway output and thus the amount of GGPP available for catabolism.
geranylgeranyl diphosphate catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GGDPS | Cancer; isoprenoid-dependent proliferation | GGDPS knockout or point-mutation cancer cell lines |
| HMGCR | Cardiovascular disease; statin response | HMGCR overexpression and statin-treated cells |
| RHO/RAC1 | Autoimmunity; cytoskeletal signaling | Prenylation-deficient knock-in models |
| ABCA1 | Reverse cholesterol transport; monocyte function | ABCA1 reporter and bisphosphonate-treated monocytoid cells |
| MVK | Mevalonate kinase deficiency | MVK point-mutation cell models |
Cancer and GGDPS inhibition
GGDPS is the enzyme that produces GGPP, and its inhibition reduces the substrate available for geranylgeranylation of oncogenic small GTPases. Because GGPP catabolism controls the free GGPP pool, changes in this process can influence cancer cell proliferation and survival. Structural studies of GGDPS support the development of inhibitors that indirectly modulate GGPP catabolic flux.
Autoimmunity and T cell biology
T cell receptor engagement modulates the mevalonate pathway and regulates T follicular helper cell generation in homeostasis and autoimmunity. GGPP-dependent prenylation is part of this metabolic control, linking GO:1902247 to immune cell fate decisions. Dysregulated isoprenoid metabolism may therefore contribute to autoimmune pathology.
Aging and oocyte quality
Mevalonate metabolites, including GGPP, boost aged oocyte quality through prenylation of small GTPases. This finding connects GGPP availability and catabolism to reproductive aging. Interventions that alter isoprenoid flux may affect oocyte developmental competence.
Metabolic and cardiovascular pharmacology
Bisphosphonates such as ibandronate stimulate reverse cholesterol transport out of monocytoid cells by enhancing ABCA1 transcription, a process linked to isoprenoid metabolism. Statins reduce mevalonate pathway flux and can alter GGPP-dependent signaling. These pharmacological connections make GO:1902247 relevant to cardiovascular and bone disease research.
From geranylgeranyl diphosphate catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GGDPS alter GGPP catabolic flux? | GGDPS knockout cell line |
| Does a specific prenylation site on RHO control signaling? | RHO point-mutation knock-in |
| Can GGPP catabolism be monitored in live cells? | Tagged GGPP-binding protein knock-in |
| Does overexpression of GGDPS increase prenylation? | GGDPS overexpression cell model |
| How does TCR engagement change mevalonate flux? | T cell activation model with metabolic readouts |
| Does bisphosphonate treatment affect ABCA1? | Monocytoid cell line with ABCA1 reporter |
How to Study the geranylgeranyl diphosphate catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | GGPP and isoprenoid levels | Quantifying catabolic flux |
| Alkyne-isoprenoid labeling | Protein geranylgeranylation | Prenylation profiling |
| Immunoblotting | Prenylated small GTPases | RHO/RAC/RAB modification status |
| Live-cell imaging | Membrane localization of GTPases | Cytoskeletal and trafficking studies |
| CRISPR knockout | Loss-of-function of GGDPS or HMGCR | Causal testing of catabolic genes |
| Reporter assays | ABCA1 transcription | Bisphosphonate response |
| Isotope tracing | Mevalonate pathway flux | Metabolic pathway analysis |
| Structural biology | GGDPS active site | Inhibitor design |
Metabolomics and GGPP quantification
Mass spectrometry-based metabolomics can quantify GGPP and related isoprenoids in cell extracts, providing a direct readout of catabolic flux. Stable isotope labeling of mevalonate pathway intermediates helps trace GGPP turnover. These methods are essential for linking genotype to metabolic phenotype in GO:1902247 studies.
Prenylation assays
Protein geranylgeranylation can be assessed by immunoblotting for prenylated RHO, RAC or RAB proteins, or by metabolic labeling with alkyne-containing isoprenoid analogs. These assays measure the functional consequence of GGPP availability and catabolism. Changes in prenylation are a sensitive indicator of flux through GO:1902247.
Imaging of isoprenoid-dependent localization
Fluorescence imaging of GFP-tagged small GTPases can reveal changes in membrane localization that depend on geranylgeranylation. Mononuclear phagocyte morphology and chemotaxis are sensitive to GGPP levels and can be imaged in live cells. Such imaging connects GGPP catabolism to cell behavior.
Genetic and pharmacological perturbation
Knockout, knockdown or overexpression of GGDPS, HMGCR and prenyltransferases, combined with statins or bisphosphonates, allows researchers to manipulate GGPP catabolic flux. These perturbations can be paired with metabolomic and prenylation readouts to build causal models.
How CRISPR Can Be Used to Study GO:1902247 geranylgeranyl diphosphate catabolic process
Knockout
CRISPR knockout of GGDPS or HMGCR can reduce GGPP synthesis and indirectly lower catabolic flux, allowing researchers to test the requirement for GGPP in prenylation and cell signaling. Knockout of prenyltransferase subunits such as PGGT1B or RABGGTA blocks GGPP consumption and can cause GGPP accumulation. These models are useful for dissecting the directionality of GO:1902247 in disease phenotypes.
Point Mutation
Point mutations in GGDPS or in the prenylation sites of RHO, RAC or RAB can separate catalytic activity from substrate recognition. Such models help determine whether a specific residue is required for GGPP binding or for downstream signaling. They are also valuable for studying inherited metabolic variants.
Knock-in
Knock-in of tagged GGDPS or tagged small GTPases enables live-cell tracking of GGPP-dependent localization and turnover. Fluorescent or affinity tags allow biochemical purification of prenylated proteins. These models bridge metabolic flux and protein function.
Overexpression
Overexpression of GGDPS increases GGPP production and can drive prenylation-dependent phenotypes. Overexpression of ABCA1 or other downstream effectors can test whether catabolic flux changes are sufficient to alter cholesterol transport. These models are useful for gain-of-function studies in cancer and metabolic disease.
How EDITGENE Supports geranylgeranyl diphosphate catabolic process Research
Researchers studying geranylgeranyl diphosphate catabolic process-related genes often need to determine whether a candidate gene is causally involved in GGPP turnover, prenylation or disease phenotypes. EDITGENE provides CRISPR-based cell model services that allow precise manipulation of these genes in relevant cell types, enabling functional validation of metabolic and signaling hypotheses.
Contact EDITGENE today to design your custom CRISPR model for geranylgeranyl diphosphate catabolic process research.
Frequently Asked Questions About geranylgeranyl diphosphate catabolic process
What is GO:1902247?
GO:1902247 is the Gene Ontology term for geranylgeranyl diphosphate catabolic process, the chemical reactions and pathways that break down GGPP.
What is geranylgeranyl diphosphate catabolic process?
It is the biological process that removes GGPP from the cellular pool through dephosphorylation, conversion to other isoprenoids, oxidative degradation or use in protein geranylgeranylation.
What genes are involved in geranylgeranyl diphosphate catabolic process?
Key genes include GGDPS, HMGCR, FDPS, prenyltransferase subunits such as PGGT1B and RABGGTA, and small GTPases like RHO, RAC1 and RAB.
Why is GGPP catabolism important?
It controls the substrate available for protein geranylgeranylation, which regulates small GTPase function, cell signaling, immune cell fate and oocyte quality.
How is geranylgeranyl diphosphate catabolic process studied?
Researchers use metabolomics, prenylation assays, live-cell imaging and CRISPR knockout or overexpression models.
What diseases are linked to GGPP metabolism?
Cancer, autoimmunity, aging-related oocyte decline and cardiovascular or bone disease pharmacology are linked to GGPP metabolism.
What is the role of GGDPS in GGPP catabolism?
GGDPS produces GGPP, so its activity determines how much substrate is available for catabolic removal and prenylation.
Can statins affect geranylgeranyl diphosphate catabolic process?
Statins inhibit HMG-CoA reductase and reduce mevalonate pathway flux, indirectly lowering GGPP availability and catabolic flux.
What experimental models are used for GO:1902247?
Knockout, point-mutation, knock-in and overexpression cell models, combined with metabolic and imaging readouts, are commonly used.
How does EDITGENE support GGPP catabolism research?
EDITGENE provides CRISPR knockout, point-mutation, knock-in, overexpression, library screening and bioinformatics services for genes in this pathway.
Conclusion
GO:1902247, geranylgeranyl diphosphate catabolic process, is a biologically_process term that captures the breakdown of GGPP, a central isoprenoid metabolite. Its importance lies in controlling the substrate pool for protein geranylgeranylation and in linking mevalonate pathway flux to cell signaling, immune function, aging and disease. Researchers can study this process using metabolomics, prenylation assays, imaging and CRISPR-based cell models. EDITGENE offers a full suite of CRISPR services to support functional studies of GGPP catabolism-related genes.
References
- 1. Liu C et al.. 2025. Mevalonate metabolites boost aged oocyte quality through prenylation of small GTPases.. Nat Aging 5(10):2022-2038 PMID: 40858817
- 2. McTaggart SJ. 2006. Isoprenylated proteins.. Cell Mol Life Sci 63(3):255-67 PMID: 16378247
- 3. Muehlebach ME et al.. 2023. Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.. Clin Transl Med 13(1):e1167 PMID: 36650113
- 4. Wang L et al.. 2026. Modulation of the mevalonate pathway by TCR engagement regulates T follicular helper cell generation in homeostasis and autoimmunity.. Immunity 59(7):1911-1927.e12 PMID: 42134327
- 5. Krauklis SA et al.. 2024. Mononuclear phagocyte morphological response to chemoattractants is dependent on geranylgeranyl pyrophosphate.. Am J Physiol Endocrinol Metab 327(1):E55-E68 PMID: 38717364
- 6. Strobach D et al.. 2003. The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription.. Biochem Biophys Res Commun 307(1):23-30 PMID: 12849976
- 7. Pham AC et al.. 2024. Structural Insight into Geranylgeranyl Diphosphate Synthase (GGDPS) for Cancer Therapy.. Mol Cancer Ther 23(1):14-23 PMID: 37756579
- 8. Kawamukai M. 2018. Biosynthesis and applications of prenylquinones.. Biosci Biotechnol Biochem 82(6):963-977 PMID: 29457959
